NEW YORK STATE COMMON RETIREMENT FUND - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
NEW YORK STATE COMMON RETIREMENT FUND ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$4
-95.8%
3,555
-94.7%
0.00%
Q2 2023$95
-90.5%
67,600
+7353.1%
0.00%
Q2 2022$1,000
-99.1%
907
-98.7%
0.00%
Q1 2022$106,000
-37.3%
69,129
+0.3%
0.00%
Q4 2021$169,000
-2.9%
68,922
-0.3%
0.00%
Q3 2021$174,000
-41.2%
69,150
-33.4%
0.00%
Q2 2021$296,000
+410.3%
103,900
+49.5%
0.00%
Q1 2020$58,000
-6.5%
69,5000.0%0.00%
Q4 2019$62,000
-8.8%
69,5000.0%0.00%
Q3 2019$68,00069,5000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders